Slocum, Gordon & CO LLP Abb Vie Inc. Transaction History
Slocum, Gordon & CO LLP
- $512 Million
- Q3 2024
A detailed history of Slocum, Gordon & CO LLP transactions in Abb Vie Inc. stock. As of the latest transaction made, Slocum, Gordon & CO LLP holds 40,174 shares of ABBV stock, worth $7.23 Million. This represents 1.55% of its overall portfolio holdings.
Number of Shares
40,174
Previous 42,456
5.37%
Holding current value
$7.23 Million
Previous $7.28 Million
8.94%
% of portfolio
1.55%
Previous 5.67%
Shares
8 transactions
Others Institutions Holding ABBV
# of Institutions
3,853Shares Held
1.25BCall Options Held
16.8MPut Options Held
12.2M-
Vanguard Group Inc Valley Forge, PA172MShares$30.9 Billion0.62% of portfolio
-
Black Rock Inc. New York, NY136MShares$24.6 Billion0.54% of portfolio
-
State Street Corp Boston, MA79.1MShares$14.2 Billion0.65% of portfolio
-
Jpmorgan Chase & CO New York, NY52.1MShares$9.38 Billion0.84% of portfolio
-
Morgan Stanley New York, NY38.7MShares$6.97 Billion0.56% of portfolio
About AbbVie Inc.
- Ticker ABBV
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,768,099,968
- Market Cap $318B
- Description
- AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...